-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

Benzinga·10/08/2026 11:52:46
Listen to the news
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.